Viyash Scientific Limited · NSE:VIYASH
Viyash Scientific — SeQuent Scientific — Q4 FY24 Earnings Presentation
17 slides from Viyash Scientific's earnings presentation, May 15, 2024
Slide 1: Proven Ability In Life Sciences
Proven Ability In Life Sciences May 15, 2024 To, BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex, Dalal Street, Fort, Bandra (East), Mumbai – 400 001. Mumbai – 400 051. Scrip cod
Slide 2: Earnings Presentation Q4 FY24
SeQuent Scientific Limited Earnings Presentation Q4 FY24 May 2024
Slide 3: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "pl
Slide 4: Sequent – At a glance
equent — At a glance oN eS
Slide 5: Sequent Scientific – At a glance
Sequent Scientific – At a glance 30+ India’s Only USFDA approved API Largest Animal Health 5 Global R&D centres company from Years of facility dedicated for Animal Health APIs India Market Excellence 7* 9 100+ State of the art Strategic acquisitions Countries with marketing manufacturing facilities
Slide 6: Global presence – Seven manufacturing plants spread across three continents
Global presence – Seven manufacturing plants spread across three continents SeQuent Scientific Limited 5
Slide 7: An unwavering commitment to a culture of quality and responsible business operations
An unwavering commitment to a culture of quality and responsible business operations Mahad Vizag Regulatory • WHO – Geneva certifications Solar Energy Reforestation Hazardous Waste • EDQM (Sept-16) Reduction • CEP – • Installed 73 kW of Planted 1,400 trees 27% reduction in Albendazole USFDA solar ca
Slide 8: Q4 and FY24 Performance Update
Q4 and FY24 Performance Update
Slide 9: Sequent Q4 FY24 – Earnings Release
Sequent Q4 FY24 – Earnings Release It gives me immense satisfaction to share that our transformation program, which began late last year, has continued to deliver according to plan. In Q4 FY24, the company achieved its highest EBITDA (pre-ESOP costs) in the last 12 quarters of INR 411mn. The EBITDA
Slide 10: Sequent Q4 FY24 – Key Highlights
Sequent Q4 FY24 – Key Highlights • Highest EBITDA (pre-ESOP cost) in twelve quarters at INR 411 mn; Pre-ESOP cost EBITDA growth of 36% / 221% q-o-q / y-o-y • 11.4% EBITDA margin – expanded by 220 / 790 bps q-o-q / y-o-y Business Results • Q4FY24 Revenue 9.7% q-o-q reported (+7.5% in constant currenc
Slide 11: Sustained margin expansion throughout FY24 – exited FY24 at 11.4%
Sustained margin expansion throughout FY24 – exited FY24 at 11.4%, in line with guidance 450 0 70. 00% Q4FY24 Pre-ESOP 11.4% cost EBITDA: 9.2% 411 400 0 60. 00% INR 411 mn 302 350 0 7.4% 7.6% 277 263 50. 00% +36% q-o-q 300 0 3.5% 2.8% +221% y-o-y 128 93 46.1% 45.1% 45.2% 42.1% 40. 00% 41.5% 250 0 39
Slide 12: Q4 FY24: Revenue Performance – by geography
Q4 FY24: Revenue Performance – by geography All values in ₹ Mn QnQ Gr% YoY Gr% YoY Gr% Revenue Distribution Q4 FY24 Q3 FY24 QnQ Gr% Q4 FY23 YoY Gr% FY24 FY23 YoY Gr% (In cc) (In cc) (In cc) Formulations 2,476 2,510 -1.4% -2.1% 2,559 -3.3% 2.2% 9,997 10,021 -0.2% -0.5% Europe 1,236 1,269 -2.5% -3.2%
Slide 13: Q4 and FY24 Consolidated Financials
Q4 and FY24 Consolidated Financials All values in ₹ Mn Q4 Q3 Q4 Grw Grw YoY Grw YoY • 660 bps of y-o-y Gross Margin Particulars FY24 FY23 FY24 FY24 FY23 QnQ % % % improvement in Q4 FY24: Revenue from Operations 3,612 3,294 3,667 10% -1% 13,697 14,209 -4% Material Consumption (1,945) (1,806) (2,217)
Slide 14: Q4 and FY24 Consolidated B/S – Key Items
Q4 and FY24 Consolidated B/S – Key Items All values in ₹ Mn Particulars Mar-24* Dec-23 Mar-23* • Net Debt – Part repayment of existing loans Shareholders' 6,566 6,631 6,981 • Working Capital – Receivables increase on account of higher Funds dispatches in API and Turkey in Q4 Minority Interest 564 55
Slide 15: Recap of key initiatives in FY24
Recap of key initiatives in FY24 Large scale operational excellence program focused on cost optimization and margin improvement Project Pragati - APIs started in H2FY23; meaningful benefits in H2FY24 with further improvement anticipated in FY25 • Discontinuation of API / Intermediates manufacturing
Slide 16: For details, feel free to contact
For details, feel free to contact: Phillip Trott Abhishek Singhal Company Secretary Investor Relations Consultant +91 22 4111 4777 abhishek.s@sequent.in investorrelations@sequent.in Registered Office: 301/A, ‘Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Maharashtra, I
Slide 17: Thank You
Thank You oN eS